Table 2.
Sample characteristics by gender for partners of People with Cancer (PPWC)
| |
Women |
Men |
Test for group difference |
Significance |
Effect size |
||
|---|---|---|---|---|---|---|---|
| Variable | n | M (SD) | n | M (SD) | F | p | η2 |
| Partner age |
87 |
54.1 (13.5) |
61 |
54.8 (11.1) |
0.11 |
0.738 |
0.001 |
| Years since partner’s first diagnosis |
87 |
2.9 (2.0) |
61 |
2.9 (2.0) |
0.01 |
0.932 |
0.000 |
| Length of current relationship |
87 |
25.0 (16.2) |
61 |
23.8 (13.2) |
0.24 |
0.629 |
0.002 |
| |
n |
% |
n |
% |
χ2 |
p |
φ |
| Ethnicity: |
|
|
|
|
0.85 |
0.653 |
0.056 |
| Aust/White European |
82 |
97.6 |
57 |
95.0 |
|
|
|
| Asian |
1 |
1.2 |
2 |
3.3 |
|||
| Other |
1 |
1.2 |
1 |
1.7 |
|||
| Cancer type: |
|
|
|
|
60.10 |
<0.001 |
0.297 |
| Breast |
4 |
4.6 |
29 |
48.3 |
|
|
|
| Gynecologic |
4 |
4.6 |
9 |
15 |
|||
| Prostate |
35 |
40.2 |
2 |
3.3 |
|||
| Genitourinary (other) |
6 |
6.9 |
- |
- |
|||
| Hematological/Blood |
15 |
17.2 |
10 |
16.7 |
|||
| Digestive/Gastrointestinal |
11 |
12.6 |
6 |
10.0 |
|||
| Neurologic |
2 |
2.3 |
1 |
1.7 |
|||
| Skin |
2 |
2.3 |
1 |
1.7 |
|||
| Othera |
8 |
9.2 |
2 |
3.3 |
|||
| Cancer classification: |
|
|
|
|
1.60 |
0.207 |
0.104 |
| Sexual cancer type |
49 |
56.3 |
40 |
66.7 |
|
|
|
| Non-sexual cancer type |
38 |
43.7 |
20 |
33.3 |
|||
| Stage of disease: |
|
|
|
|
3.11 |
0.375 |
0.095 |
| No longer detectable/In remission |
52 |
59.8 |
41 |
67.2 |
|
|
|
| Receiving treatment |
2 |
2.3 |
3 |
4.9 |
|||
| Otherb |
33 |
37.9 |
17 |
27.9 |
|||
| Relationship status: |
|
|
|
|
0.12 |
0.896 |
0.011 |
| Partnered – Living together |
79 |
90.8 |
55 |
90.2 |
|
|
|
| Partnered – Not living together |
8 |
9.2 |
6 |
9.8 |
|||
| Sexual orientation: |
|
|
|
|
36.16 |
0.525 |
0.086 |
| Heterosexual |
79 |
90.8 |
55 |
90.2 |
|
|
|
| Non heterosexual |
8 |
9.2 |
6 |
9.8 |
|||
| Current sexual relationship: |
|
|
|
|
0.12 |
0.729 |
0.039 |
| Yes |
70 |
81.4 |
51 |
83.6 |
|||
| No | 16 | 18.6 | 10 | 16.4 | |||
Note a “Other” includes: Respiratory/Thoracic, Head & Neck, various, each less than 1.5%; b “Other” includes: a new different cancer; active monitoring; outcome not specified.